NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis $2.45 +0.05 (+2.08%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.38▼$2.5250-Day Range$2.10▼$4.2052-Week Range$1.12▼$13.51Volume702,713 shsAverage Volume752,034 shsMarket Capitalization$561.88 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ProKidney alerts: Email Address ProKidney MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside76.9% Upside$4.33 Price TargetShort InterestBearish15.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 4 Articles This WeekInsider TradingAcquiring Shares$74.74 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector729th out of 936 stocksBiological Products, Except Diagnostic Industry123rd out of 154 stocks 3.2 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProKidney has only been the subject of 2 research reports in the past 90 days.Read more about ProKidney's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.85% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 5.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 2.6 News and Social Media Coverage News SentimentProKidney has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ProKidney this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for PROK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have bought 106,162.30% more of their company's stock than they have sold. Specifically, they have bought $74,735,338.00 in company stock and sold $70,331.00 in company stock.Percentage Held by Insiders41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProKidney's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to remain at ($0.56) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ProKidney's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About ProKidney Stock (NASDAQ:PROK)ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More PROK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROK Stock News HeadlinesJune 26, 2024 | insidertrades.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Acquires 8,264,462 Shares of StockJuly 25 at 6:33 PM | finance.yahoo.comChronic Kidney Disease for Seven Major Markets: US, France, Germany, Italy, Spain, UK, Japan Drug Forecasts and Analysis 2023-2033July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.30June 27, 2024 | investorplace.comPROK Stock Earnings: ProKidney Reported Results for Q4 2023June 11, 2024 | globenewswire.comProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingJune 10, 2024 | globenewswire.comProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingJune 10, 2024 | globenewswire.comProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational UpdatesJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 29, 2024 | globenewswire.comProKidney to Participate in the Jefferies Global Healthcare ConferenceMay 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProKidney on Rilparencel’s Promising Efficacy in CKD TreatmentMay 23, 2024 | seekingalpha.comProKidney: Date Due In Several Days May Enhance Bull Thesis, But I'm SkepticalMay 21, 2024 | globenewswire.comProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024May 11, 2024 | finance.yahoo.comWe're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash WiselyMay 10, 2024 | finance.yahoo.comProKidney Corp Reports First Quarter 2024 Financial ResultsMay 10, 2024 | investorplace.comPROK Stock Earnings: ProKidney Beats EPS for Q1 2024May 10, 2024 | globenewswire.comProKidney Reports Business Updates and First Quarter 2024 Financial ResultsApril 26, 2024 | finance.yahoo.comDiabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032See More Headlines Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$4.33 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+79.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,470,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-8.09% Debt Debt-to-Equity RatioN/A Current Ratio17.62 Quick Ratio17.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.84) per share Price / Book-0.50Miscellaneous Outstanding Shares229,340,000Free Float134,189,000Market Cap$555.00 million OptionableOptionable Beta1.10 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Bruce Culleton M.D. (Age 56)CEO & Director Comp: $657.93kDr. Timothy A. Bertram D.V.M. (Age 69)Ph.D., Founder Comp: $1.46MMr. James Coulston CPA (Age 47)Chief Financial Officer Comp: $533.15kMr. Todd C. Girolamo Esq. (Age 59)J.D., M.B.A., Chief Legal Officer & Secretary Comp: $541.59kMs. Mary Weger (Age 65)Chief People Officer Dr. Joseph M. Stavas M.D.M.P.H., Senior VP of Interventional Procedures & Patient SafetyDr. Darin J. Weber Ph.D. (Age 56)Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access Mr. Nikhil L. Pereira-KamathChief Business OfficerMr. Richard WilliamsSenior Vice President of Information TechnologyDr. Aparna Sahoo M.D.VP & Head of Global Clinical DevelopmentMore ExecutivesKey CompetitorsSOAR Technology AcquisitionNYSE:FLYASemper Paratus AcquisitionNASDAQ:LGSTAkiliNASDAQ:AKLIGetaroundNYSE:GETRRecursion PharmaceuticalsNASDAQ:RXRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 55,266 shares on 7/26/2024Ownership: 0.078%Pablo G LegorretaBought 22,617,909 shares on 6/13/2024Total: $54.74 M ($2.42/share)Control Empresarial De CapitalBought 8,264,462 shares on 6/11/2024Total: $20.00 M ($2.42/share)Darin J WeberSold 17,238 sharesTotal: $70,331.04 ($4.08/share)Vanguard Group Inc.Sold 1,085,965 shares on 5/10/2024Ownership: 0.791%View All Insider TransactionsView All Institutional Transactions PROK Stock Analysis - Frequently Asked Questions How have PROK shares performed this year? ProKidney's stock was trading at $1.78 on January 1st, 2024. Since then, PROK stock has increased by 37.6% and is now trading at $2.45. View the best growth stocks for 2024 here. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) posted its earnings results on Friday, May, 10th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09. Who are ProKidney's major shareholders? ProKidney's top institutional shareholders include Bank of New York Mellon Corp (0.08%). Insiders that own company stock include Control Empresarial De Capital and Darin J Weber. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
